The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Clomipramine vs Desipramine Crossover Trial in Body Dysmorphic Disorder: Selective Efficacy of a Serotonin Reuptake Inhibitor in Imagined Ugliness
Abstract
BACKGROUND: Body dysmorphic disorder (preoccupation with an imagined or slight defect in appearance) is a common and disabling disorder associated with high rates of delusional symptoms and suicide attempts. Although preliminary studies suggest that serotonin reuptake inhibitors may be effective for body dysmorphic disorder, to date no controlled treatment studies have been published. METHODS: Forty patients were enrolled and 29 were randomized into a 16-week, double-blind, crossover-design study of clomipramine, a potent serotonin reuptake inhibitor, and active control desipramine, a selective norepinephrine reuptake inhibitor. Outcome measures included specific ratings of body dysmorphic disorder severity, delusionality, and functional impairment. RESULTS: Clomipramine was superior to desipramine in the acute treatment of body dysmorphic disorder symptoms as measured by assessment of patients' obsessive preoccupation with perceived body defects, repetitive behaviors in response to this preoccupation, and global ratings of symptom severity. Treatment efficacy was independent of the presence or severity of comorbid diagnoses of obsessive-compulsive disorder, depression, or social phobia. Likewise, clomipramine was equally effective regardless of whether the patients had insight or held their dysmorphic misperception with delusional intensity. Clomipramine was also superior to desipramine in improving functional disability. CONCLUSIONS: Clomipramine is more effective than desipramine in the treatment of body dysmorphic disorder and is effective even among those patients who are delusional.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712 · cited 2×
“Depression severity was assessed by the 24-item Hamilton Depression Rating Scale (HAM-D).17 Obsessive-compulsive disorder severity was assessed by the YBOCS.11,12 Social anxiety severity was assessed by 2 self-administered, true-false questionnaires that do not explicitly measure social phobia, but are widely used to…”
MethodMeasurement of social-evaluative anxiety.
Watson, D., & Friend, R. (1969) · Journal of Consulting and Clinical Psychology · doi:10.1037/h0027806 · Cited by 3,467
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
(1997) · PubMed · Cited by 664
Body dysmorphic disorder: 30 cases of imagined ugliness
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.2.302 · Cited by 582
Functional impairment in social phobia.
Schneier, F. R., Heckelman, L., Garfinkel, R. S., Campeas, R. B., Fallon, B. A., Gitow, A., Street, L. L., Bene, D. D., & Liebowitz, M. R. (1994) · PubMed · Cited by 534
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.90 · Cited by 521
Goodman, W. K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810180077011 · Cited by 311
Hudak, R., & Gannon, J. M. (2022) · Current Clinical Practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306
A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases.
Phillips, K. A., McElroy, S. L., Keck, P. E., Hudson, J. I., & Pope, H. G. (1994) · PubMed · Cited by 244
Efficacy and Safety of Fluvoxamine in Body Dysmorphic Disorder
Phillips, K. A., Dwight, M. M., & McElroy, S. L. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0404 · Cited by 182
Treatment of body-dysmorphic disorder with serotonin reuptake blockers
Hollander, E., Liebowitz, M. R., Winchel, R., Klumker, A., & Klein, D. F. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.6.768 · Cited by 153
Self-citationBody dysmorphic disorder in the DSM-IV field trial for obsessive- compulsive disorder
Simeon, D., Hollander, E., Stein, D. J., Cohen, L. J., & Aronowitz, B. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1207 · Cited by 136
Self-citation
Cited by
The prevalence of body dysmorphic disorder: a population-based survey
RIEF, W., BUHLMANN, U., WILHELM, S., BORKENHAGEN, A., & BRÄHLER, E. (2006) · Psychological Medicine · doi:10.1017/s0033291706007264 · Cited by 453
Surgical and Nonpsychiatric Medical Treatment of Patients With Body Dysmorphic Disorder
Phillips, K. A., Grant, J., Siniscalchi, J., & Albertini, R. S. (2001) · Psychosomatics · doi:10.1176/appi.psy.42.6.504 · Cited by 368
Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?
Phillips, K. A., Stein, D. J., Rauch, S. L., Hollander, E., Fallon, B. A., Barsky, A., Fineberg, N., Mataix-Cols, D., Ferrão, Y. A., Saxena, S., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20705 · Cited by 347
Self-citationPathophysiology of obsessive–compulsive disorder
Aouizerate, B., Guehl, D., Cuny, E., Rougier, A., Bioulac, B., Tignol, J., & Burbaud, P. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.02.004 · Cited by 341
A Randomized Placebo-Controlled Trial of Fluoxetine in Body Dysmorphic Disorder
Phillips, K. A., Albertini, R. S., & Rasmussen, S. A. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.4.381 · Cited by 321
Metadata
- Authors
- Hollander, E., Allen, A., Kwon, J., Aronowitz, B., Schmeidler, J., Wong, C., & Simeon, D.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-11-01
- Volume
- 56
- Issue
- 11
- Pages
- 1033
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W1982058060
- Cited by
- 275
- References
- 15
- FWCI
- 14.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.